Banco Bilbao Vizcaya Argentaria S.A. Has $32.19 Million Stock Position in Eli Lilly and Company $LLY

Banco Bilbao Vizcaya Argentaria S.A. increased its holdings in Eli Lilly and Company (NYSE:LLY) by 18.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,313 shares of the company’s stock after acquiring an additional 6,544 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Eli Lilly and Company were worth $32,186,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Nixon Peabody Trust Co. lifted its holdings in shares of Eli Lilly and Company by 63.6% in the second quarter. Nixon Peabody Trust Co. now owns 19,510 shares of the company’s stock valued at $15,209,000 after purchasing an additional 7,588 shares in the last quarter. Clearstead Trust LLC raised its position in Eli Lilly and Company by 1.2% in the 2nd quarter. Clearstead Trust LLC now owns 4,860 shares of the company’s stock valued at $3,789,000 after buying an additional 57 shares during the last quarter. Wiser Advisor Group LLC lifted its stake in Eli Lilly and Company by 1.8% during the 2nd quarter. Wiser Advisor Group LLC now owns 4,299 shares of the company’s stock valued at $3,351,000 after acquiring an additional 77 shares in the last quarter. Allianz SE boosted its holdings in Eli Lilly and Company by 3.3% during the 2nd quarter. Allianz SE now owns 40,499 shares of the company’s stock worth $31,570,000 after acquiring an additional 1,298 shares during the last quarter. Finally, Thompson Davis & CO. Inc. boosted its holdings in Eli Lilly and Company by 3.7% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 1,662 shares of the company’s stock worth $1,296,000 after acquiring an additional 60 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on LLY shares. JPMorgan Chase & Co. dropped their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Cantor Fitzgerald upped their target price on Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Finally, Berenberg Bank reaffirmed a “hold” rating and set a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $999.32.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,022.00 on Friday. The business’s 50 day simple moving average is $820.93 and its 200 day simple moving average is $779.85. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,032.95. The company has a market cap of $966.19 billion, a price-to-earnings ratio of 66.80, a PEG ratio of 1.21 and a beta of 0.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the previous year, the company posted $1.18 earnings per share. The business’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.